Tumorigenic de-differentiation: the alternative splicing way. (1st November 2020)

• Record Type: Journal Article
• Authors: Ray, Debleena; Epstein, David M.
• Is Part Of: Molecular & cellular oncology. Volume 7:Number 6(2020)
• Publication Date: 2020-11-01
• Subjects: MBNL1 -- MAP2K7 -- JNK -- JNK inhibitors -- alternative splicing -- cancer cell de-differentiation -- cancer stem cells -- RNA binding proteins -- splice factors; Tumors -- Periodicals; Neoplasms; Periodicals; 616.99
• DOI: 10.1080/23723556.2020.1809959
• Languages: English
• ISSNs: 2372-3556

Abstract

ABSTRACT: The mechanism of acquisition of tumorigenic properties by somatic cells at the onset of cancer and later during relapse is a question of paramount importance in cancer biology. We have recently discovered a Muscleblind like-1 (MBNL1)-driven alternative-splicing mediated mechanism of tumorigenic de-differentiation that is associated with poor prognosis, relapse and metastasis in common cancer types.